Study of BLU-808 in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- Registration Number
- NCT06948032
- Lead Sponsor
- Blueprint Medicines Corporation
- Brief Summary
This is a 3-part study. Parts 1 and 2 are randomized, double-blind, placebo-controlled investigations of single ascending doses (SAD) (Part 1) and multiple ascending doses (MAD) (Part 2) of orally administered BLU-808 in healthy adult participants. Part 2 will also include an evaluation of the effect of multiple doses of BLU-808 on the single-dose pharmacokinetics (PK) of midazolam. Part 3 is an open-label, 2-sequence, 2-period, food effect (FE) study in healthy adult participants.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 95
Inclusion Criteria
- Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to the first dosing based on subject self-reporting.
- Medically healthy with no clinically significant medical history, physical examination, clinical laboratory profiles, or vital signs, as deemed by the Principal Investigator (PI) or designee.
- No clinically significant cardiac history as judged by the PI or designee at the screening visit and check-in.
Key
Exclusion Criteria
- Participant is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
- Participant has history or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI, designee, or Sponsor.
- Participant has history or presence of alcohol or drug abuse within the past 2 years prior to the first dosing.
- Participant has positive results at the screening visit for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).
- Participant has been on a diet incompatible with the on-study diet (that is, unusual meal habits and special diet requirements or unwillingness to eat the food provided in the trial), in the opinion of the PI or designee, within the 30 days prior to the first dosing and throughout the study.
- Participant has participated in another clinical study within 30 days prior to the first dosing. The 30-day window will be derived from the date of the last dosing in the previous study to the first dosing of the current study.
- Participant has positive coronavirus disease 2019 (COVID-19) results at first check-in.
Note: Other protocol-specified inclusion and exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Part 1: BLU-808 BLU-808 BLU-808 will be administered orally. Part 1: Placebo Placebo Matching placebo for BLU-808 will be administered orally. Part 2: BLU-808 BLU-808 BLU-808 will be administered orally. Part 2: Placebo Placebo Matching placebo for BLU-808 will be administered orally. Part 2: Midazolam Alone Followed by BLU-808 and Midazolam BLU-808 Participants will receive oral midazolam in Period 1. Participants will then receive oral BLU-808 with midazolam in period 2. Part 2: Midazolam Alone Followed by BLU-808 and Midazolam Midazolam Participants will receive oral midazolam in Period 1. Participants will then receive oral BLU-808 with midazolam in period 2. Part 2: Midazolam Alone Followed by BLU-808 Matching Placebo and Midazolam Placebo Participants will receive oral midazolam in Period 1. Participants will then receive oral matching placebo for BLU-808 with midazolam in period 2. Part 2: Midazolam Alone Followed by BLU-808 Matching Placebo and Midazolam Midazolam Participants will receive oral midazolam in Period 1. Participants will then receive oral matching placebo for BLU-808 with midazolam in period 2. Part 3: BLU-808 (Treatment D, E) BLU-808 BLU-808 will be administered orally. Part 3: BLU-808 (Treatment E, D) BLU-808 BLU-808 will be administered orally.
- Primary Outcome Measures
Name Time Method Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Up to Day 20 Part 2: Number of Participants With TEAEs Up to Day 50 Part 3: Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Non-zero Concentration (AUC0-t) Up to Day 6 Part 3: Maximum Observed Plasma Concentration (Cmax) Up to Day 6
- Secondary Outcome Measures
Name Time Method Part 1: AUC0-t Up to Day 6 Part 1: Cmax Up to Day 6 Part 1: Terminal Elimination Half-life (t1/2) Up to Day 6 Part 1: Change From Baseline in QTc (Corrected Value of the Interval Between the Q and T Waves on the Electrocardiogram Tracing) Up to Day 6 Parts 1 and 2: Change From Baseline in Serum Tryptase Concentrations Up to Day 6 Part 2: AUC0-t Up to Day 14 Part 2: Cmax Up to Day 14 Part 2: t1/2 Up to Day 19 Part 3: Number of Participants With TEAEs Up to Day 26
Trial Locations
- Locations (1)
Celerion, Inc.
🇺🇸Lincoln, Nebraska, United States